Vera Therapeutics

VERA Rare disease Lead: Approved 7 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Catalyst timeline

Atacicept readout3Q 2026Atacicept readout, 3Q 2026, material
Atacicept PIONEER Ph2 readout4Q 2026Atacicept PIONEER Ph2 readout, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

TRUTAKNA

atacicept · atacicept-vymj

Protein Target: BAFF, APRIL, TACI

IgA Nephropathy Approved subcutaneous Ares Trading NCT04716231
Primary Membranous Nephropathy Phase 2 subcutaneous Ares Trading NCT06983028
Focal Segmental Glomerulosclerosis Phase 2 subcutaneous Ares Trading NCT06983028
Minimal Change Disease Phase 2 subcutaneous Ares Trading NCT06983028

MAU868

Protein Target: BKV VP1, BK virus

BK Virus Infection Phase 2 intravenous Novartis NCT04294472

VT-109

Protein Target: BAFF, APRIL

Undisclosed indication Preclinical Stanford

Biotech Distilled coverage (7)

2026-08-11 UPDATE: Vera Therapeutics (VERA) - The Post-Approval Hangover 🔒 Paid
2026-07-07 UPDATE: Vera Therapeutics (VERA) - The Lazarus Drug Gets Its Label 🔒 Paid
2026-06-02 UPDATE: Vera Therapeutics (VERA) - The Full Approval Clock Just Moved Up a Year
2026-03-07 UPDATE: Vera Therapeutics (VERA) - VERA Adds an M&A Heavyweight to the Board 🔒 Paid
2026-02-28 UPDATE: Vera Therapeutics (VERA) - FY25 Wrap-Up 🔒 Paid
2026-01-07 UPDATE: Vera Therapeutics (VERA) Hits the Accelerator – FDA Grants Priority Review 🔒 Paid
2025-12-16 Vera Therapeutics (VERA): Scientific Due Diligence for Atacicept and Pipeline 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.